ESPERION THERAPEUTICS, INC.

(ESPR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Goldman Sachs Adjusts Esperion Therapeutics' Price Target to $5 from $8, Keeps Sell Rating

12/06/2021 | 10:53am EDT


© MT Newswires 2021
All news about ESPERION THERAPEUTICS, INC.
05/17Esperion to Participate in Upcoming H.C. Wainwright Global Investment Conference
GL
05/17Esperion to Participate in Upcoming H.C. Wainwright Global Investment Conference
AQ
05/10TRANSCRIPT : Esperion Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Confe..
CI
05/05JPMorgan Upgrades Esperion Therapeutics to Neutral From Underweight; Price Target is $6
MT
05/03ESPERION THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
05/03TRANSCRIPT : Esperion Therapeutics, Inc., Q1 2022 Earnings Call, May 03, 2022
CI
05/03ESPERION THERAPEUTICS : Q1 Earnings Snapshot
AQ
05/03Earnings Flash (ESPR) ESPERION THERAPEUTICS Reports Q1 Loss $-0.93, vs. Street Est of $..
MT
05/03Earnings Flash (ESPR) ESPERION THERAPEUTICS Posts Q1 Revenue $18.8M, vs. Street Est of ..
MT
05/03Esperion Reports First Quarter 2022 Financial Results and Provides Company Update
GL
More news
Analyst Recommendations on ESPERION THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 82,0 M - -
Net income 2022 -222 M - -
Net Debt 2022 172 M - -
P/E ratio 2022 -1,67x
Yield 2022 -
Capitalization 382 M 382 M -
EV / Sales 2022 6,77x
EV / Sales 2023 1,93x
Nbr of Employees -
Free-Float 96,0%
Chart ESPERION THERAPEUTICS, INC.
Duration : Period :
Esperion Therapeutics, Inc. Technical Analysis Chart | ESPR | US29664W1053 | MarketScreener
Technical analysis trends ESPERION THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Last Close Price 6,07 $
Average target price 10,41 $
Spread / Average Target 71,5%
EPS Revisions
Managers and Directors
Sheldon L. Koenig President, Chief Executive Officer & Director
William J. Sasiela Senior Vice President-Clinical Development
Ken Fiorelli Chief Technical Operations Officer
JoAnne Micale Foody Chief Medical Officer
Nicole Vitullo Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ESPERION THERAPEUTICS, INC.21.40%382
JOHNSON & JOHNSON2.59%461 811
PFIZER, INC.-14.65%282 789
ABBVIE INC.12.58%269 361
ELI LILLY AND COMPANY6.87%265 718
ROCHE HOLDING AG-15.26%264 329